These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
393 related articles for article (PubMed ID: 33637115)
1. SMYD3: a regulator of epigenetic and signaling pathways in cancer. Bernard BJ; Nigam N; Burkitt K; Saloura V Clin Epigenetics; 2021 Feb; 13(1):45. PubMed ID: 33637115 [TBL] [Abstract][Full Text] [Related]
2. Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation. Van Aller GS; Reynoird N; Barbash O; Huddleston M; Liu S; Zmoos AF; McDevitt P; Sinnamon R; Le B; Mas G; Annan R; Sage J; Garcia BA; Tummino PJ; Gozani O; Kruger RG Epigenetics; 2012 Apr; 7(4):340-3. PubMed ID: 22419068 [TBL] [Abstract][Full Text] [Related]
3. Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer. Patani N; Jiang WG; Newbold RF; Mokbel K Anticancer Res; 2011 Dec; 31(12):4115-25. PubMed ID: 22199269 [TBL] [Abstract][Full Text] [Related]
4. Histone lysine methyltransferase SMYD3 promotes oral squamous cell carcinoma tumorigenesis via H3K4me3-mediated HMGA2 transcription. Yang Z; Liu F; Li Z; Liu N; Yao X; Zhou Y; Zhang L; Jiang P; Liu H; Kong L; Lang C; Xu X; Jia J; Nakajima T; Gu W; Zheng L; Zhang Z Clin Epigenetics; 2023 May; 15(1):92. PubMed ID: 37237385 [TBL] [Abstract][Full Text] [Related]
5. Lysine methylation in cancer: SMYD3-MAP3K2 teaches us new lessons in the Ras-ERK pathway. Colón-Bolea P; Crespo P Bioessays; 2014 Dec; 36(12):1162-9. PubMed ID: 25382779 [TBL] [Abstract][Full Text] [Related]
6. Structural Basis for Substrate Preference of SMYD3, a SET Domain-containing Protein Lysine Methyltransferase. Fu W; Liu N; Qiao Q; Wang M; Min J; Zhu B; Xu RM; Yang N J Biol Chem; 2016 Apr; 291(17):9173-80. PubMed ID: 26929412 [TBL] [Abstract][Full Text] [Related]
7. Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription. Kim H; Heo K; Kim JH; Kim K; Choi J; An W J Biol Chem; 2009 Jul; 284(30):19867-77. PubMed ID: 19509295 [TBL] [Abstract][Full Text] [Related]
8. Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents. Rajajeyabalachandran G; Kumar S; Murugesan T; Ekambaram S; Padmavathy R; Jegatheesan SK; Mullangi R; Rajagopal S Expert Opin Ther Targets; 2017 Feb; 21(2):145-157. PubMed ID: 28019723 [TBL] [Abstract][Full Text] [Related]
9. Molecular implementation and physiological roles for histone H3 lysine 4 (H3K4) methylation. Shilatifard A Curr Opin Cell Biol; 2008 Jun; 20(3):341-8. PubMed ID: 18508253 [TBL] [Abstract][Full Text] [Related]
10. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Mazur PK; Reynoird N; Khatri P; Jansen PW; Wilkinson AW; Liu S; Barbash O; Van Aller GS; Huddleston M; Dhanak D; Tummino PJ; Kruger RG; Garcia BA; Butte AJ; Vermeulen M; Sage J; Gozani O Nature; 2014 Jun; 510(7504):283-7. PubMed ID: 24847881 [TBL] [Abstract][Full Text] [Related]
11. Smyd3-associated regulatory pathways in cancer. Giakountis A; Moulos P; Sarris ME; Hatzis P; Talianidis I Semin Cancer Biol; 2017 Feb; 42():70-80. PubMed ID: 27554136 [TBL] [Abstract][Full Text] [Related]
12. SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters. Zhang H; Zheng Z; Zhang R; Yan Y; Peng Y; Ye H; Lin L; Xu J; Li W; Huang P Cell Death Dis; 2021 Jul; 12(8):731. PubMed ID: 34301921 [TBL] [Abstract][Full Text] [Related]
13. Elevated placental histone H3K4 methylation via upregulated histone methyltransferases SETD1A and SMYD3 in preeclampsia and its possible involvement in hypoxia-induced pathophysiological process. Matsui H; Iriyama T; Sayama S; Inaoka N; Suzuki K; Yoshikawa M; Ichinose M; Sone K; Kumasawa K; Nagamatsu T; Fujisawa T; Naguro I; Ichijo H; Fujii T; Osuga Y Placenta; 2021 Nov; 115():60-69. PubMed ID: 34560329 [TBL] [Abstract][Full Text] [Related]
14. The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3. Liu C; Fang X; Ge Z; Jalink M; Kyo S; Björkholm M; Gruber A; Sjöberg J; Xu D Cancer Res; 2007 Mar; 67(6):2626-31. PubMed ID: 17363582 [TBL] [Abstract][Full Text] [Related]
15. Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy. Shen B; Tan M; Mu X; Qin Y; Zhang F; Liu Y; Fan Y Tumour Biol; 2016 Jun; 37(6):7371-81. PubMed ID: 26676636 [TBL] [Abstract][Full Text] [Related]
16. SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9. Cock-Rada AM; Medjkane S; Janski N; Yousfi N; Perichon M; Chaussepied M; Chluba J; Langsley G; Weitzman JB Cancer Res; 2012 Feb; 72(3):810-20. PubMed ID: 22194464 [TBL] [Abstract][Full Text] [Related]
17. SMYD3 controls a Wnt-responsive epigenetic switch for ASCL2 activation and cancer stem cell maintenance. Wang T; Wu H; Liu S; Lei Z; Qin Z; Wen L; Liu K; Wang X; Guo Y; Liu Q; Liu L; Wang J; Lin L; Mao C; Zhu X; Xiao H; Bian X; Chen D; Xu C; Wang B Cancer Lett; 2018 Aug; 430():11-24. PubMed ID: 29746925 [TBL] [Abstract][Full Text] [Related]
18. On your histone mark, SET, methylate! Binda O Epigenetics; 2013 May; 8(5):457-63. PubMed ID: 23625014 [TBL] [Abstract][Full Text] [Related]
19. Using Yeast to Define the Regulatory Role of Protein Lysine Methylation. Jethmalani Y; Green EM Curr Protein Pept Sci; 2020; 21(7):690-698. PubMed ID: 31642774 [TBL] [Abstract][Full Text] [Related]
20. The SMYD3-MAP3K2 signaling axis promotes tumor aggressiveness and metastasis in prostate cancer. Ikram S; Rege A; Negesse MY; Casanova AG; Reynoird N; Green EM Sci Adv; 2023 Nov; 9(46):eadi5921. PubMed ID: 37976356 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]